Patent US4465358A successfully refreshed from Google Patents.
Patent US4454339A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4454339A Expired / Lapsed US ⏱️ 0.0 years remaining

9-Fluoroprostaglandin derivatives, and use as medicinal agents

Assignee: Bayer Pharma AG
•
Filing: 1982-07-06
•
Granted: 1984-06-12
•
Expires: 2002-07-06
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract 9-Fluoroprostane derivatives of Formula I ##STR1## wherein R 1 is CH 2 OH or ##STR2## wherein R 2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R 1 is the residue ##STR3## wherein R 3 is an acid residue or R 2 and A is --CH 2 --CH 2 -- or cis--CH═CH--, B is --CH 2 --CH 2 --, trans--CH═CH-- or --C.tbd.C, W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the α- or β-position, D and E jointly are a direct bond or D is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen or sulfur, a direct bond, --C.tbd.C-- or --CR 6 ═CR 7 -- wherein R 6 and R 7 differ from each other and each is hydrogen, chlorine, or alkyl, R 4 is a free or functionally modified hydroxy group, and R 5 is hydrogen, an optionally substituted aliphatic group, e.g., alkyl or halosubstituted alkyl, cycloalkyl, optionally substituted aryl or a heterocyclic group, and, when R 2 is H, physiologically compatible salts thereof with bases, have valuable pharmacological properties, e.g., as luteolytics or abortifacients.

Inventors

  • 👤 Werner Skuballa
  • 👤 Bernd Raduechel
  • 👤 Norbert Schwarz
  • 👤 Helmut Vorbrueggen
  • 👤 Walter Elger
  • 👤 Olaf Loge
  • 👤 Michael-Harold Town

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 22:41
CPC Classifications
C; C07; C07C; C07C405/00; A; A61; A61P; A61P43/00; C07C405/0008; C07C405/0016; C07C405/0041

Claims Analysis

Total Claims: 29
Claim 1
Independent Claim 435 words
A 9-Fluoroprostane derivative of the formula ##STR18## wherein R 1 is CH 2 OH or ##STR19## wherein R 2 is (a) hydrogen, (b) C 1-10 alkyl, (c) C 1-10 alkyl substituted by halogen; C 1-4 alkoxy; C 6-10 -aryl or aroyl; C 6-10 -aryl or aroyl each substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group; di-C 1-4 -alkylamino; or tri-C 1-4 -alkylammonium; (d) C 3-10 cycloalkyl, (e) C 3-10 cycloalkyl substituted by C 1-4 alkyl, (f) C 6-10 aryl, (g) C 6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group, or (h) an aromatic heterocycle of 5 or 6 ring atoms, one or two of which are O, N or S, the remainder being carbon atoms; or R 1 is ##STR20## wherein R 3 is an acyl group of a hydrocarbon C 1-5 carboxylic or sulfonic acid or is one of the R 2 groups; A is --CH 2 --CH 2 -- or cis--CH═CH--; B is --CH 2 --CH 2 --, trans--CH═CH-- or C.tbd.C--; W is hydroxymethylene or RO-methylene, wherein the OR or OH group is in a α- or β-position; R is tetrahydropyranyl, tetrahydrofuranyl, α-ethoxyethyl, trimethylsilyl, dimethyl-tert-butylsilyl, tribenzylsilyl or an acyl group of a C 1-5 -hydrocarbon carboxylic or sulfonic acid. D and E jointly are a direct bond or D is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms, optionally substituted by 1-2 fluorine atoms and E is oxygen, sulfur, a direct bond, C.tbd.C-- or --CR 6 ═CR 7 -- wherein R 6 and R 7 differ from each other and each is hydrogen, chlorine or C 1-6 -alkyl; R 4 is OH or OR; R 5 is (a) a C 6-10 hydrocarbon aliphatic radical substituted by C 6-10 -aryl or by C 6-10 -aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, caboxy, hydroxy or C 1-4 alkoxy group; (b) C 3-10 cycloalkyl, (c) C 3-10 cycloalkyl substituted by C 1-4 alkyl; (d) C 6-10 aryl, (e) C 6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group; or (f) an aromatic heterocycle of 5 or 6 ring atoms, one or two of which are O, N or S, the remainder being carbon atoms; or when R 2 is hydrogen, a physiologically compatible salt thereof with a base.
Claim 2
Dependent Claim 435 words
A 9-Fluoroprostane derivative of the formula ##STR18## wherein R 1 is CH 2 OH or ##STR19## wherein R 2 is (a) hydrogen, (b) C 1-10 alkyl, (c) C 1-10 alkyl substituted by halogen; C 1-4 alkoxy; C 6-10 -aryl or aroyl; C 6-10 -aryl or aroyl each substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group; di-C 1-4 -alkylamino; or tri-C 1-4 -alkylammonium; (d) C 3-10 cycloalkyl, (e) C 3-10 cycloalkyl substituted by C 1-4 alkyl, (f) C 6-10 aryl, (g) C 6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group, or (h) an aromatic heterocycle of 5 or 6 ring atoms, one or two of which are O, N or S, the remainder being carbon atoms; or R 1 is ##STR20## wherein R 3 is an acyl group of a hydrocarbon C 1-5 carboxylic or sulfonic acid or is one of the R 2 groups; A is --CH 2 --CH 2 -- or cis--CH═CH--; B is --CH 2 --CH 2 --, trans--CH═CH-- or C.tbd.C--; W is hydroxymethylene or RO-methylene, wherein the OR or OH group is in a α- or β-position; R is tetrahydropyranyl, tetrahydrofuranyl, α-ethoxyethyl, trimethylsilyl, dimethyl-tert-butylsilyl, tribenzylsilyl or an acyl group of a C 1-5 -hydrocarbon carboxylic or sulfonic acid. D and E jointly are a direct bond or D is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms, optionally substituted by 1-2 fluorine atoms and E is oxygen, sulfur, a direct bond, C.tbd.C-- or --CR 6 ═CR 7 -- wherein R 6 and R 7 differ from each other and each is hydrogen, chlorine or C 1-6 -alkyl; R 4 is OH or OR; R 5 is (a) a C 6-10 hydrocarbon aliphatic radical substituted by C 6-10 -aryl or by C 6-10 -aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, caboxy, hydroxy or C 1-4 alkoxy group; (b) C 3-10 cycloalkyl, (c) C 3-10 cycloalkyl substituted by C 1-4 alkyl; (d) C 6-10 aryl, (e) C 6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group; or (f) an aromatic heterocycle of 5 or 6 ring atoms, one or two of which are O, N or S, the remainder being carbon atoms; or when R 2 is hydrogen, a physiologically compatible salt thereof with a base.
Claim 3
Dependent Claim 17 words
A compound of claim 1 wherein B-W-D-E-R 5 is ##STR21## wherein Y 1 is halo or H.
Claim 4
Dependent Claim 8 words
(5Z,13E)-(9R,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-5,13-prostadienoic acid methyl ester, compound of claim 1.
Claim 5
Dependent Claim 9 words
(5Z,13E)-(9S,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-5,13-prostadienoic acid methyl ester, a compound of claim 1.
Claim 6
Dependent Claim 9 words
(13E)-(9R,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-13-prostenoic acid methyl ester, a compound of claim 1.
Claim 7
Dependent Claim 9 words
(13E)-(9S,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-13-prostenoic acid methyl ester, a compound of claim 1.
Claim 8
Dependent Claim 7 words
(5Z,13E)-(9R,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-5,13-prostadienoic acid, a compound of claim 1.
Claim 9
Dependent Claim 7 words
(5Z,13E)-(9S,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-5,13-prostadienoic acid, a compound of claim 1.
Claim 10
Dependent Claim 7 words
(13E)-(9R,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-13-prostenoic acid, a compound of claim 1.
Claim 11
Dependent Claim 7 words
(13E)-(9S,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-13-prostenoic acid, a compound of claim 1.
Claim 12
Dependent Claim 6 words
(13E)-(9R,11R,15R)-9-Fluoro-1,11,15-trihydroxy-16-phenoxy-17,18,19,20-tetranor-13-prostene, a compound of claim 1.
Claim 13
Dependent Claim 6 words
(13E)-(9S,11R,15R)-9-Fluoro-1,11,15-trihydroxy-16-phenoxy-17,18,19,20-tetranor-13-prostene, a compound of claim 1.
Claim 14
Dependent Claim 8 words
(13E)-(9R,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-13-prostenoic acid methylsulfonamide, a compound of claim 1.
Claim 15
Dependent Claim 8 words
(13E)-(9S,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-13-prostenoic acid methylsulfonamide, a compound of claim 1.
Claim 16
Dependent Claim 8 words
(13E)-(9R,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-13-prostenoic acid isopropylsulfonamide, a compound of claim 1.
Claim 17
Dependent Claim 8 words
(13E)-(9R,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-13-prostenoic acid acetylamide, a compound of claim 1.
Claim 18
Dependent Claim 8 words
(13E)-(9R,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-13-prostenoic acid amide, a compound of claim 1.
Claim 19
Dependent Claim 9 words
(5Z,13E)-(9R,11R,15R)-11,15-Dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-5,13-prostadienoic acid tris(hydroxymethyl)aminomethane salt, a compound of claim 1.
Claim 20
Dependent Claim 21 words
A pharmaceutical composition comprising an amount of a compound of claim 1 effective to trigger luteolysis and a pharmaceutically acceptable carrier.
Claim 21
Dependent Claim 37 words
A method of achieving a luteolytic effect in a patient in whom it is desired to achieve such an effect comprising administering to the patient an amount of a compound of claim 1 effective to trigger luteolysis.
Claim 22
Dependent Claim 410 words
A 9-Fluoroprostane derivative of the formula ##STR22## wherein R 1 is CH 2 OH or ##STR23## wherein R 2 is (a) hydrogen, (b) C 1-10 alkyl, (c) C 1-10 alkyl substituted by halogen; C 1-14 alkoxy; C 6-10 -aryl or aroyl; C 6-10 -aryl or aroyl each substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group; di-C 1-4 -alkylamino; or tri-C 1-4 -alkylammonium; (d) C 3-10 cycloalkyl, (e) C 3-10 cycloalkyl substituted by C 1-4 alkyl, (f) C 6-10 aryl, (g) C 6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group, or (h) an aromatic heterocycle of 5 or 6 ring atoms, one or two of which are O, N or S, the remainder being carbon atoms; or R 1 is ##STR24## wherein R 3 is an acyl group of a hydrocarbon C 1-15 carboxylic or sulfonic acid or is one of the R 2 groups; A is --CH 2 --CH 2 -- or cis--CH═CH--; B is --CH 2 --CH 2 --, trans--CH═CH-- or C.tbd.C--; W is hydroxymethylene or RO-methylene, wherein the OR or OH group is in a α- or β-position; R is tetrahydropyranyl, tetrahydrofuranyl, α-ethoxyethyl, trimethylsilyl, dimethyl-tert-butylsilyl, tribenzylsilyl or an acyl group of a C 1-15 -hydrocarbon carboxylic or sulfonic acid, D is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms, optionally substituted substituted by 1-2 fluorine atoms and E is oxygen, sulfur or C.tbd.C--; R 4 is OH or OR; R 5 is (a) hydrogen, (b) a C 1-10 hydrocarbon aliphatic radical, (c) a C 6-10 hydrocarbon aliphatic radical substituted by halogen, C 6-10 -aryl or by C 6-10 -aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group; (d) C 3-10 cycloalkyl, (e) C 3-10 cycloalkyl substituted by C 1-4 alkyl; (f) C 6-10 aryl, (g) C 6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group; or (h) an aromatic heterocyce of 5 or 6 ring atoms, one or two of which are O, N or S, the remainder being carbon atoms; or when R 2 is hydrogen a physiologically compatible salt thereof with a base.
Claim 23
Dependent Claim 410 words
A 9-Fluoroprostane derivative of the formula ##STR22## wherein R 1 is CH 2 OH or ##STR23## wherein R 2 is (a) hydrogen, (b) C 1-10 alkyl, (c) C 1-10 alkyl substituted by halogen; C 1-14 alkoxy; C 6-10 -aryl or aroyl; C 6-10 -aryl or aroyl each substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group; di-C 1-4 -alkylamino; or tri-C 1-4 -alkylammonium; (d) C 3-10 cycloalkyl, (e) C 3-10 cycloalkyl substituted by C 1-4 alkyl, (f) C 6-10 aryl, (g) C 6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group, or (h) an aromatic heterocycle of 5 or 6 ring atoms, one or two of which are O, N or S, the remainder being carbon atoms; or R 1 is ##STR24## wherein R 3 is an acyl group of a hydrocarbon C 1-15 carboxylic or sulfonic acid or is one of the R 2 groups; A is --CH 2 --CH 2 -- or cis--CH═CH--; B is --CH 2 --CH 2 --, trans--CH═CH-- or C.tbd.C--; W is hydroxymethylene or RO-methylene, wherein the OR or OH group is in a α- or β-position; R is tetrahydropyranyl, tetrahydrofuranyl, α-ethoxyethyl, trimethylsilyl, dimethyl-tert-butylsilyl, tribenzylsilyl or an acyl group of a C 1-15 -hydrocarbon carboxylic or sulfonic acid, D is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms, optionally substituted substituted by 1-2 fluorine atoms and E is oxygen, sulfur or C.tbd.C--; R 4 is OH or OR; R 5 is (a) hydrogen, (b) a C 1-10 hydrocarbon aliphatic radical, (c) a C 6-10 hydrocarbon aliphatic radical substituted by halogen, C 6-10 -aryl or by C 6-10 -aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group; (d) C 3-10 cycloalkyl, (e) C 3-10 cycloalkyl substituted by C 1-4 alkyl; (f) C 6-10 aryl, (g) C 6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C 1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C 1-4 alkoxy group; or (h) an aromatic heterocyce of 5 or 6 ring atoms, one or two of which are O, N or S, the remainder being carbon atoms; or when R 2 is hydrogen a physiologically compatible salt thereof with a base.
Claim 24
Dependent Claim 21 words
A pharmaceutical composition comprising an amount of a compound of claim 21 effective to trigger luteolysis and a pharmaceutically acceptable carrier.
Claim 25
Dependent Claim 37 words
A method of achieving a luteolytic effect in a patient in whom it is desired to achieve such an effect comprising administering to the patient an amount of a compound of claim 21 effective to trigger luteolysis.
Claim 26
Dependent Claim 24 words
A pharmaceutical composition comprising an amount of a compound of claim 1 effective to reduce swelling of nasal mucous membranes and a pharmaceutically-acceptable carrier.
Claim 27
Dependent Claim 13 words
A pharmaceutical composition of claim 24, wherein the active ingredient is (5Z,13E)-(9R,11R,15R)-11,15-dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-5,13-prostadienoic acid.
Claim 28
Dependent Claim 39 words
A method of reducing the swelling of nasal mucous membranes a patient in need of such treatment comprising administering to the patient an amount of a compound of claim 1 effective to reduce the swelling of nasal mucous membranes.
Claim 29
Dependent Claim 12 words
A method of claim 26 wherein the active ingredient is (5Z,13E)-(9R,11R,15R)-11,15-dihydroxy-9-fluoro-16-phenoxy-17,18,19,20-tetranor-5,13-prostadienoic acid.

References Cited (Backward Citations)

DE2628364A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-06-12 1987-12-12 1988-06-12 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-06-12 1991-12-12 1992-06-12 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-06-12 1995-12-12 1996-06-12 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag